Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size

Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer

This study has been completed.
Sponsor:
Information provided by:
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT00103831
First received: February 15, 2005
Last updated: February 27, 2010
Last verified: August 2008
History of Changes
  Purpose

A phase I-II dose ranging study of BMS-275183 (oral taxane) in combination with pemetrexed (Alimta) in patients with recurrent Non-Small Cell Lung Cancer (NSCLC). The safety and efficacy of this combination will be studied.


Condition Intervention Phase
Non-small Cell Lung Cancer
 Drug: Oral Taxane
 Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Primary Purpose: Treatment
Official Title: Phase I Alimta Combination With BMS-275183 (Oral Taxane)

Resource links provided by NLM:

MedlinePlus related topics: Lung Cancer
U.S. FDA Resources

Further study details as provided by Bristol-Myers Squibb:
Primary Completion Date: May 2005 (Final data collection date for primary outcome measure)
  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Advanced or metastatic pretreated NSCLC
  • Measurable disease
  • Adequate hematologic, hepatic and renal functions.
  • ECOG Performance Status 0-2

Exclusion Criteria:

  • Inability to swallow capsules
  • Recent significant cardiovascular disease
  • Women who are pregnant or breastfeeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00103831

Locations
United States, Colorado
Local Institution
Denver, Colorado, United States
United States, Minnesota
Local Institution
Rochester, Minnesota, United States
Canada, Ontario
Local Institution
Toronto, Ontario, Canada
Sponsors and Collaborators
Bristol-Myers Squibb
  More Information

Additional Information:
BMS Clinical Trials Disclosure  This link exits the ClinicalTrials.gov site
For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm  This link exits the ClinicalTrials.gov site

No publications provided

ClinicalTrials.gov Identifier: NCT00103831     History of Changes
Other Study ID Numbers: CA165-021
Study First Received: February 15, 2005
Last Updated: February 27, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Bristol-Myers Squibb:
NSCLC - non-small cell lung cancer

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Bronchial Neoplasms
Carcinoma, Bronchogenic
Lung Diseases
Lung Neoplasms
 Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms

ClinicalTrials.gov processed this record on March 03, 2015